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Background: Hematopoetic stem cell transplants (HSCT) are discussed as treatment options for patients with
solid tumors. Transplant numbers have changed substantially over the last decade, few controlled studies are
available and different opinions prevail. Objective information on current practice is needed.
Patients and methods: Data from 27 902 HSCT for solid tumors (2% allogeneic, 98% autologous), collected
by the European Group for Blood and Marrow Transplantation (EBMT) activity survey from 1991 to 2002 were
used to assess trends, transplant rates and coefficient of variation of transplant rates in Europe.
Results: Transplant numbers increased from 536 in 1991 to 4154 in 1997 and decreased to 1913 in 2002.
Indications were neuroblastoma (2504 HSCT; 9%), glioma (662 HSCT; 2%), soft tissue sarcoma (1253 HSCT;
4%), germ cell cancer (3291 HSCT; 12%), breast cancer (13 524 HSCT; 48%), Ewing’s sarcoma (1896 HSCT;
7%), lung cancer (387 HSCT; 1%), ovarian cancer (845 HSCT; 3%) and other solid tumors (3540 HSCT; 14%).
Allogeneic cells were used in <20 cases up to 1997; since then allogeneic HSCT increased to 159 in 2002,
mainly for renal cell carcinoma. Low coefficients of variation in transplant rates (<60%) are observed for
Ewing’s sarcoma (<56.5%), suggesting consensus for this indication.
Conclusions: These data give an overview on current practice of HSCT for solid tumors in Europe. They
provide objective information for health-care providers and patient counselling.
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Introduction
Intensive chemotherapy supported by hematopoietic stem cell
transplantation (HSCT) has been considered a useful approach for
patients with chemo-radiosensitive malignancies for many years.
Hematopoetic stem cells could overcome the dose-limiting
marrow toxicity of more intensive regimens [1–8]. Triggered by
preliminary positive, retrospective and prospective data in the
early 1990s, enthusiasm has fostered HSCT as a treatment
approach for breast cancer, and transplant numbers have increased
massively over several years for breast cancer and other tumors
alike. This trend was supported by positive prospective ran-
domized trials in hematological malignancies with a parallel
increase in transplant numbers for lymphomas and leukemias
[9–13]. A change in attitude occurred in 1997. Doubts on initial
reports, failures of prospective controlled studies to document an
advantage of HSCT in breast cancer, and rising awareness of the
need for evidence brought about this change. HSCT numbers for
breast cancer declined [14]. For other indications transplants con-
tinued, based in part on results of controlled studies, such as for
neuroblastoma [15], or in the context of such studies. Definitive
answers are still lacking. Optimal information is not available.
Patients and treating physicians in contrast depend on an optimum
of information for treatment decisions today. Large comprehen-
sive observational databases provide an instrument to reflect
current strategies. Taking the annual European Group for Blood
and Marrow Transplantation (EBMT) activity survey as a basis,
we therefore present a detailed analysis of current practice of
HSCT for solid tumors in Europe, including changes over time in
transplant numbers and differences in transplant rates between
European countries over the last 12 years. The results describe
current thinking of specialist teams in Europe.
Patients and methods
Data collection, selection and validation
Data derived for these analyses come from the EBMT activity surveys intro-
duced in 1990 [16]. All EBMT members and affiliated non-members receive
an annual survey sheet on which they report numbers of patients by indication,
stem cell source and donor type for the past year. This report includes data
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from 1991 up to and including 2002. This analysis includes solid tumors
defined and classified in 1991 as neuroblastoma, glioma, soft tissue cancer,
germ cell cancer, breast cancer, Ewing’s sarcoma, lung cancer, ovarian cancer
and other solid tumors. Lung cancer and ovarian cancer were introduced as
new variables in 1997 (Table 1). Specific information on melanoma or renal
carcinoma has only been introduced in 2002.
The EBMT survey forms an integral part of a prospective quality assurance
program conducted by the EBMT (http://www.ebmt.org). Validation of data
includes returning a computer printout of entered data to the reporting teams,
cross-checking with national transplant registries and onsite visits.
Participating countries and teams
The report is based on 636 teams from 39 European countries. The numbers
have increased from 143 teams in 1990 to the current status [16]. For the 2002
report, there were responses from 586 teams. Twenty-six contacted teams
chose for unknown reasons not to reply, or failed to do so, despite several
efforts to reach them. No major transplant team in Europe is missing from the
list. Of the 586 teams reporting HSCT in 2002, 331 (57%) do both allogeneic
and autologous transplants; 230 teams (39%) restrict their activity to auto-
logous, eight teams (1%) to allogeneic transplants only. Seventeen contacted
teams (3%) did not perform transplants in 2002.
Contacted teams are listed in the Appendix in alphabetical order according
to country, city and EBMT center code. This can be viewed online at
www.annonc.oupjournals.org. Information reached us that no blood or marrow
transplants were performed in Albania, Andorra, Armenia, Azerbaijan, Bosnia-
Herzegovina, Georgia, Iceland, Liechtenstein, Malta, Moldavia, Monaco, San
Marino and the Vatican during this time period.
Definitions
Transplants. Transplants were defined by the EBMT (http://www.EBMT.org)
as the infusion of hematopoetic stem cells following a conditioning regimen
with the intention of replacing the existing hematopoesis by injected stem
cells. The information in this analysis is restricted to first transplants, e.g. refers
to individual patients not to transplant numbers. Patients in planned double or
triple transplant programs are counted only once.
Transplant rates. Transplant rates were defined as the number of HSCT per
10 million inhabitants. They were computed for each disease indication, donor
type and country. For each disease indication, transplant rates were assessed
for all HSCT and separately for autologous and allogeneic HSCT. Population
data were obtained from the US Census Office (http://www.census.gov).
Coefficient of variation. Transplant rates from those countries with more than
300 HSCT in 2002 (Austria, Belgium, Czech Republic, France, Germany,
Italy, The Netherlands, Poland, Spain, Sweden, Turkey and the UK) were used
to calculate the coefficient of variation (CV) of transplant rates for each disease
indication. It was calculated as previously defined [17] by computing mean
and standard deviations as follows: CV (%) = (standard deviation/mean)
× 100. Low CVs reflect little variation in transplant rates, high CVs high
variation in transplant rates between the selected countries.
Team density. Team densities were defined as the number of transplant teams
in participating countries per 10 million inhabitants.
Statistical analysis
Mean, median and standard deviations of numerical variables were calculated
on an Excel spreadsheet. Groups were compared with chi-square tests. Ta
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Results
Numbers and donor type of HSCT for solid tumors from 
1991 to 2002
A total of 27 902 HSCT, 27 318 (98%) autologous and 584 (2%)
allogeneic, were carried out in Europe from 1991 to 2002 (Table 1).
There were 2504 HSCT for neuroblastoma (9%), 662 HSCT for
glioma (2%), 1253 HSCT for soft tissue sarcoma (4%), 3291
HSCT for germ cell cancer (12%), 13 524 HSCT for breast cancer
(49%), 1896 HSCT for Ewing’s sarcoma (7%), 387 HSCT for
lung cancer (1%), 845 HSCT for ovarian cancer (3%), 3540 for
‘others’ (13%).
The change in numbers and absolute numbers of HSCT per year
for the main disease categories is presented in Table 1 and illus-
trated in Figure 1. There is an increase in HSCT for neuroblastoma,
glioma, soft tissue sarcoma, germ cell cancer, Ewing’s sarcoma
and ‘other’ indications. There is an increase initially followed by a
decrease for breast cancer, lung cancer and ovarian cancer. Trans-
plants increased 2.6-fold for neuroblastoma, 1.1-fold for glioma,
3.0-fold for soft tissue, 2.7-fold for germ cell, 3.5-fold for breast
cancer (28-fold from 1991 to 1997), 5.9-fold for Ewing’s sarcoma
and 5.3-fold for ‘others’ from 1991 to 2002.
Primarily autologous HSCT were used for all indications with
few allogeneic transplants, as presented in Table 1. Up to 10%
allogeneic transplants were seen early in the 1990s for Ewing’s
sarcoma with a decline thereafter. The proportion of allogeneic
HSCT is increasing again in the most recent years for soft tissue
sarcoma, breast cancer, ovarian cancer and ‘others’, with a total
159 allogeneic HSCT in 2002. Based on this recent increase in
allogeneic HSCT for solid tumors, renal cell carcinoma and
melanoma were introduced as specific new variables to the activity
survey in 2002.
Trend over time
This evolution of transplant numbers over time for allogeneic and
autologous HSCT is best illustrated by separation into disease
subcategories (Figure 2). Different trends can be observed. There
is a continuous steady increase in autologous HSCT for neuro-
blastoma (Figure 2A) and Ewing’s sarcoma (Figure 2B). For
glioma (Figure 2A), soft tissue sarcoma (Figure 2B) and germ cell
tumors (Figure 2D), numbers have been stable over the obser-
vation period. This is in sharp contrast to the evolution in breast
cancer (Figure 2E), ovarian (Figure 2C) and lung cancer (Figure
2C). The increase up to 1997 is followed by a sharp decrease. For
allogeneic HSCT the numbers remain low in all disease indica-
tions with the exception of other disease categories (Figure 2F). A
marked increase is observed over the last 3 years and is primarily
due to renal cell carcinoma (80 HSCT in 2002), breast cancer (14
HSCT in 2002) and colon cancer (nine HSCT in 2002).
Transplant rates in European countries
Transplant rates differed markedly between European countries,
as reflected by the distribution of the total 20 207 HSCT in Europe
in 2002 (Figure 3). Transplant rates for all transplants (Figure 3A),
including both allogeneic and autologous HSCT, varied from
0 (several countries) to more than 400 per 10 million inhabitants
(several countries). The same basic difference in transplant rates
between eastern and western European countries was observed if
autologous transplants only were considered (Figure 3B). In addi-
tion, there was a marked over- or under-representation for certain
disease indications (Figure 4). Neuroblastoma (Figure 4A), germ
cell cancer and Ewing’s sarcoma (Figure 4F) were represented in
similar proportions in all European countries. In contrast, some
tumors, such as glioma (Figure 4B), lung cancer (Figure 4G) or
ovarian cancer (Figure 4H) showed preferential distribution in
Figure 1. Numbers of hematopoetic stem cell transplants (HSCT) for solid tumors in Europe according to main disease categories from 1991 to 2002. 
Allogeneic and autologous HSCT combined.
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Figure 2. Transplant numbers for solid tumors in Europe for 1991–2002 according to disease and donor type. (A) Neuroblastoma and glioma. (B) Ewing’s 
sarcoma and soft tissue sarcoma. (C) Ovarian cancer and lung cancer. (D) Germ cell tumors. (E) Breast cancer. (F) ‘Other’ solid tumors.
Figure 3. Transplant rates in European countries, 2002. Shades reflect numbers of hematopoetic stem cell transplants (HSCT) per 10 million inhabitants. 
(A) All indications and all donor types. (B) Autologous HSCT.
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Figure 4. Transplant rates for solid tumors in Europe, 2002. Shades reflect numbers of transplants for individual indications per 10 million inhabitants. Transplant 
rates for: (A) neuroblastoma; (B) glioma; (C) soft tissue; (D) germ cell cancer; (E) breast cancer; (F) Ewing’s sarcoma; (G) lung cancer; (H) ovarian cancer.
658
selected countries, e.g. France for ovarian cancer or Switzerland
for lung cancer.
Coefficient of variation
These visual differences in transplant rates for the individual
disease indications were quantified by the coefficient of variation.
In order to adjust for the economic impact, this analysis was
restricted to 12 countries with >300 HSCT in 2002 (Table 2).
They performed a total 17 237 HSCT (all indications) in 2002
with total transplant rates from 62 (Turkey) to 578 (Italy) (median
534 transplants per 10 million inhabitants). Solid tumor transplant
rates differed substantially with numbers for neuroblastoma from
0.1 (Turkey) to 10.1 (Sweden) (median 5.5 per 10 million inhabit-
ants), for glioma from 0 (several countries) to 2.2 (France)
(median 0.4 per 10 million inhabitants), for soft tissue from 0
(several countries) to 8.5 (Austria) (median 2.3 per 10 million
inhabitants), germ cell cancer from 1.0 (Turkey) to 16.3 (Germany)
(median 4.5 per 10 million inhabitants), breast cancer from 0
(several countries) to 25.6 (Italy) (0.6 median per 10 million
inhabitants), Ewing’s sarcoma from 0.4 (Turkey) to 9.7 (Italy)
(median 5.3 per 10 million inhabitants), lung cancer from 0
(several countries) to 1.6 (Italy) (median 0.2 per 10 million inhabit-
ants), ovarian cancer from 0 (several countries) to 9.3 (France)
(median 0.7 per 10 million inhabitants), ‘other’ solid tumors from
1.8 (Turkey) to 22.6 (Italy) (median 7.9 per 10 million inhabit-
ants).
This variation of transplant rates, as exemplified by the CV, is
listed in detail for all disease indications in Table 2. Variation is
lowest for Ewing’s sarcoma (56.5) and neuroblastoma (62.9) and
is highest for breast cancer (166.4) and ovarian cancer (152.4). It
permits classification of disease into categories with high consensus
(CV <60%), intermediate consensus (CV 55–100%) and low con-
sensus (CV >100%) among the specialist teams concerning indi-
cations for HSCT. By using this approach, neuroblastoma and
Ewing’s sarcoma could be considered as accepted indications for
autologous HSCT. All other indications cannot be regarded as
established indications for HSCT.
Discussion
These data reflect current practice of HSCT for solid tumors in
Europe today, point to the changes in transplant rates over the last
decade and illustrate similarities and discrepancies between Euro-
pean countries. They illustrate the continuing increase for some
disease categories, stable situations for others, as well as increase
and decrease for indications, such as breast cancer, lung cancer
and germ cell tumors. In general these trends reflect the prevailing
considerations of transplant physicians and specialists in the field
concerning the advantage or disadvantage of HSCT: they point to
consensus on the advantage of HSCT or the need for prospective
studies. Stable low numbers reflect the experimental status of the
procedure and decreasing numbers the advent of alternative thera-
pies or a disadvantage of HSCT. In this context, it is comforting to
see that low CVs of ≤75% coincide also with those indications
where prospective randomized studies have indicated a clear
advantage, i.e. neuroblastoma or Ewing’s sarcoma [15, 18–20].
Other interpretations for high CVs are possible, as illustrated by
the difference in transplant rates for indications, such as lung
cancer or glioma. These differences reflect the impact of the
presence or absence of ongoing active study protocols by the
respective national or regional study groups [21, 22]. As such, a
lower transplant rate might reflect the absence and a higher trans-
plant rate the presence of a specific national study group protocol.
Little or no information exists with regard to these aspects.
There are several reasons for current trends in Europe regarding
autologous HSCT in solid tumors. The scenario of breast cancer
deserves some specific comments or suggestions: in the early and
mid-1990s impressive data from phase II trials as well as from
registries accelerated the growth in number of autotransplants for
this disease [1]. When the first results from phase III studies
became available, a wave of pessimism began to appear and the
number of patients undergoing high-dose chemotherapy began to
Table 2. Coefficient of variation in transplant rates for solid tumors according to disease indication in 
Europe 2002
Twelve countries with >300 HSCT in 2002 (A, B, CZ, F, G, I, NL, PL, Sp, Sw, T, UK).
A, Austria; B, Belgium; CV, coefficient of variation; CZ, Czech Republic; F, France; G, Germany; I, Italy; 
NL, The Netherlands; PL, Poland; SD, standard deviation; E, Spain; S, Sweden; T, Turkey; 
TR, transplant rate (see text for definitions).
Mean TR SD CV Country with max. TR Country with min. TR
Ewing 4.8 2.7 56.5 Italy (9.7) Turkey (0.4)
Neuroblastoma 5.1 3.2 62.9 Sweden (10.1) Turkey (0.1)
Germinal cancer 5.9 4.0 68.1 Germany (16.3) Turkey (1.0)
Soft tissue 2.6 2.7 103.6 Austria (8.5) NL, PL, S (0)
Glioma 0.8 0.9 111.2 France (2.2) B, NL E, S, T (0)
Lung cancer 0.5 0.6 127.2 Italy (1.6) CZ, NL, S, T, UK (0)
Ovarian cancer 1.8 2.8 152.4 France (9.3) CZ, NL, S, T (0)
Breast cancer 5.1 8.5 166.4 Italy (25.6) A, B, CZ, S, UK (0)
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drop [2–4, 14]. Most recent results remain ambiguous and the
value of HSCT in breast cancer still needs to be determined in
selected categories. HSCT might be an effective tool in the treat-
ment of solid tumors in some subsets of patients [23–25].
Ninety-eight per cent of all HSCT were autologous transplants.
A few allogeneic HSCT were performed in the early 1990s but
then largely abandoned. Transplant-related mortality was consid-
ered to be too high despite some documented graft-versus-tumor
effects. Interest was renewed with the introduction of reduced
intensity conditioning transplants and the first successful reports
in solid tumors [26–30]. Concepts of allogeneic HSCT for solid
tumors do not rely on high-dose chemotherapy and tumor load
reduction but rather on a graft-versus-tumor effect [26]. New
categories of solid tumors, i.e. immunosensitive malignancies,
became a target of such therapies. Focus in 1990, at the time of
introduction of the EBMT activity survey, was on chemo-sensitive
malignancies; hence, typically immunosensitive malignancies,
such as melanoma or renal cell carcinoma, were not reported in
detail but summarized as ‘others’. This has now been changed
with the introduction of renal cell carcinoma, melanoma and colon
cancer as subentities in the survey.
Comprehensive surveys like the EBMT survey, reaching >95%
of activity in the field, can provide an objective analysis of current
practice [9]. By restriction to transplants, not outcome, rapid data
collection can be attained on a broad basis. Only prospective ran-
domized studies can provide evidence on outcome differences.
Prospective randomized studies, however, take time. Additional
years are required for data analysis and for the generation of suffi-
cient observation time. This is specifically necessary if early
events, e.g. transplant-related mortality, are offset later on by
reduced relapse rate. Teams and experts in the field might change
their procedure before results are known. In these situations, the
EBMT activity survey has already become a standard instrument
to assess transplant rates and differences between European
countries. With the variation in transplant rates, difference in
opinions between transplant specialists can be quantified. Data in
2002 suggest there is consensus on autologous HSCT as an indica-
tion for Ewing’s sarcoma and near consensus on neuroblastoma
and germinal cancer in Europe.
This present analysis does not give any data on outcome. This
information is gathered elsewhere and published separately. This
survey concentrates on rapid description of the current status quo.
It reflects current practice of HSCT for solid tumors in Europe,
gives information on consensus or dissension among specialists in
the field and provides an objective basis for patient counselling
and health-care planning.
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